
## Paola Stefanelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7956778/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Did social distancing measures deployed for SARS-CoV-2/COVID-19 control have an impact on invasive meningococcal disease?. Pathogens and Global Health, 2022, 116, 263-265.	2.3	3
2	First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy. Clinical Infectious Diseases, 2022, 75, 522-524.	5.8	17
3	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. Eurosurveillance, 2022, 27, .	7.0	20
4	Evolution of SARS-CoV-2 IgG Seroprevalence in Children and Factors Associated with Seroconversion: Results from a Multiple Time-Points Study in Friuli-Venezia Giulia Region, Italy. Children, 2022, 9, 246.	1.5	6
5	Analysis of Genomic Characteristics of SARS-CoV-2 in Italy, 29 January to 27 March 2020. Viruses, 2022, 14, 472.	3.3	3
6	A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine. Journal of Community Health, 2022, 47, 598-603.	3.8	9
7	Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021. Expert Review of Vaccines, 2022, 21, 975-982.	4.4	5
8	Retrospective Analysis of Six Years of Acute Flaccid Paralysis Surveillance and Polio Vaccine Coverage Reported by Italy, Serbia, Bosnia and Herzegovina, Montenegro, Bulgaria, Kosovo, Albania, North Macedonia, Malta, and Greece. Vaccines, 2022, 10, 44.	4.4	2
9	Global spatial dynamics and vaccine-induced fitness changes of <i>Bordetella pertussis</i> . Science Translational Medicine, 2022, 14, eabn3253.	12.4	22
10	Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study. Lancet Microbe, The, 2022, 3, e452-e463.	7.3	44
11	Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy. Vaccines, 2022, 10, 778.	4.4	0
12	Reactive vaccination as control strategy for an outbreak of invasive meningococcal disease caused by Neisseria meningitidis C:P1.5-1,10-8:F3-6:ST-11(cc11), Bergamo province, Italy, December 2019 to January 2020. Eurosurveillance, 2022, 27, .	7.0	2
13	Significant increase in azithromycin "resistance―and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019. BMC Infectious Diseases, 2022, 22, .	2.9	16
14	Pediatric COVID-19 Cases Prelockdown and Postlockdown in Italy. Pediatrics, 2021, 147, .	2.1	9
15	Multiplex Real-Time Reverse-Transcription Polymerase Chain Reaction Assays for Diagnostic Testing of Severe Acute Respiratory Syndrome Coronavirus 2 and Seasonal Influenza Viruses: A Challenge of the Phase 3 Pandemic Setting. Journal of Infectious Diseases, 2021, 223, 765-774.	4.0	22
16	Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Clinical Microbiology and Infection, 2021, 27, 633.e1-633.e7.	6.0	49
17	Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. Aging Clinical and Experimental Research, 2021, 33, 193-199.	2.9	49
18	Nonrespiratory Complications and Obesity in Patients Dying with COVIDâ€19 in Italy. Obesity, 2021, 29, 20-23.	3.0	19

#	Article	IF	CITATIONS
19	Evaluation of the SpeeDxResistancePlus®GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin inNeisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 2021, 76, 84-90.	3.0	10
20	Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy. Emerging Infectious Diseases, 2021, 27, 267-270.	4.3	64
21	Evaluation of the national surveillance system for invasive meningococcal disease, Italy, 2015–2018. PLoS ONE, 2021, 16, e0244889.	2.5	5
22	Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy. Human Vaccines and Immunotherapeutics, 2021, 17, 2225-2231.	3.3	5
23	High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical <i>Neisseria gonorrhoeae</i> isolates from 25 European countries, 2018. Journal of Antimicrobial Chemotherapy, 2021, 76, 1221-1228.	3.0	31
24	Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009–2016. BMC Infectious Diseases, 2021, 21, 273.	2.9	12
25	Survey of diagnostic and typing capacity for enterovirus infection in Italy and identification of two echovirus 30 outbreaks. Journal of Clinical Virology, 2021, 137, 104763.	3.1	2
26	Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance, 2021, 26, .	7.0	216
27	Genomic Analysis and Lineage Identification of SARS-CoV-2 Strains in Migrants Accessing Europe Through the Libyan Route. Frontiers in Public Health, 2021, 9, 632645.	2.7	9
28	Emerging Non-Polio Enteroviruses recognized in the framework of the Acute Flaccid Paralyses (AFP) surveillance system in Northern Italy, 2016–2018. International Journal of Infectious Diseases, 2021, 106, 36-40.	3.3	5
29	Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study. Italian Journal of Pediatrics, 2021, 47, 131.	2.6	14
30	Comorbidity status of deceased COVID-19 in-patients in Italy. Aging Clinical and Experimental Research, 2021, 33, 2361-2365.	2.9	11
31	The Dual/Global Value of SARS-CoV-2 Genome Surveillance on Migrants Arriving to Europe via the Mediterranean Routes. Annals of Global Health, 2021, 87, 71.	2.0	5
32	First detection of SARS-CoV-2 A.23.1 sub-lineage in migrants arriving to Italy via the Mediterranean Sea and public health implications. Travel Medicine and Infectious Disease, 2021, 43, 102142.	3.0	1
33	Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease Diagnostic Microbiology and Infectious Disease, 2021, 105, 115539.	1.8	Ο
34	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. PLoS Pathogens, 2021, 17, e1009878.	4.7	52
35	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerging Microbes and Infections, 2021, 10, 710-712.	6.5	7
36	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	5.8	131

#	Article	IF	CITATIONS
37	Identification and characterization of SARS-CoV-2 clusters in the EU/EEA in the first pandemic wave: additional elements to trace the route of the virus. Infection, Genetics and Evolution, 2021, 96, 105108.	2.3	3
38	Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths. Journal of Photochemistry and Photobiology, 2021, 8, 100082.	2.5	9
39	Protective Role of Combined Polyphenols and Micronutrients against Influenza A Virus and SARS-CoV-2 Infection In Vitro. Biomedicines, 2021, 9, 1721.	3.2	23
40	Molecular characterisation and antibiotic susceptibility of meningococcal isolates from healthy men who have sex with men. Sexually Transmitted Infections, 2021, , sextrans-2021-055173.	1.9	1
41	Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, Januaryâ^'September 2021. Eurosurveillance, 2021, 26, .	7.0	20
42	The effect of COVID-19 vaccination in Italy and perspectives for living with the virus. Nature Communications, 2021, 12, 7272.	12.8	40
43	Clinical characteristics of individuals with Down syndrome deceased with CoVIDâ€19 in Italy—A case series. American Journal of Medical Genetics, Part A, 2020, 182, 2964-2970.	1.2	17
44	Sex differences in clinical phenotype and transitions of care among individuals dying of COVID-19 in Italy. Biology of Sex Differences, 2020, 11, 57.	4.1	25
45	Estimates of the reproductive numbers and demographic reconstruction of outbreak associated with C:P1.5–1,10–8:F3–6:ST–11(cc11) Neisseria meningitidis strains. Infection, Genetics and Evolution, 2020 84, 104360.	, 2.3	0
46	Selective pressure on SARS-CoV-2 protein coding genes and glycosylation site prediction. Heliyon, 2020, 6, e05001.	3.2	38
47	Geographically widespread invasive meningococcal disease caused by a ciprofloxacin resistant non-groupable strain of the ST-175 clonal complex. Journal of Infection, 2020, 81, 575-584.	3.3	9
48	Clinical Characteristics of Hospitalized Individuals Dying With COVID-19 by Age Group in Italy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1796-1800.	3.6	138
49	Laboratory management for SARS-CoV-2 detection: a user-friendly combination of the heat treatment approach and rt-Real-time PCR testing. Emerging Microbes and Infections, 2020, 9, 1393-1396.	6.5	39
50	Management of a Case of Peritonitis Due to Neisseria gonorrhoeae Infection Following Pelvic Inflammatory Disease (PID). Antibiotics, 2020, 9, 193.	3.7	6
51	Antimicrobial Resistance in Neisseria gonorrhoeae: A NewÂChallenge. , 2020, , 363-374.		1
52	Genomic analysis of the meningococcal ST-4821 complex–Western clade, potential sexual transmission and predicted antibiotic susceptibility and vaccine coverage. PLoS ONE, 2020, 15, e0243426.	2.5	7
53	Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Eurosurveillance, 2020, 25, .	7.0	134
54	Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance, 2020, 25, .	7.0	186

#	Article	IF	CITATIONS
55	Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020. Eurosurveillance, 2020, 25, .	7.0	121
56	Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014–2017. PLoS ONE, 2020, 15, e0241793.	2.5	5
57	Gene flow and Bayesian phylogeography of serogroup C meningococci circulating in Italy. Annali Dell'Istituto Superiore Di Sanita, 2020, 56, 430-436.	0.4	1
58	Pertussis: Identification, Prevention and Control. Advances in Experimental Medicine and Biology, 2019, 1183, 127-136.	1.6	10
59	Invasive meningococcal disease due to ciprofloxacin-resistant Neisseria meningitidis Sequence Type 7926: the first case in Italy, likely imported. Journal of Clobal Antimicrobial Resistance, 2019, 18, 177-178.	2.2	4
60	Genomic Characterization of Gonococci from Different Anatomic Sites, Italy, 2007–2014. Microbial Drug Resistance, 2019, 25, 1316-1324.	2.0	4
61	Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Frontiers in Immunology, 2019, 10, 1344.	4.8	105
62	Molecular Characterization of Coxsackievirus B5 Isolates from Sewage, Italy 2016–2017. Food and Environmental Virology, 2019, 11, 440-445.	3.4	6
63	Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine, 2019, 37, 991-1000.	3.8	64
64	Genomic analysis of Neisseria meningitidis carriage isolates during an outbreak of serogroup C clonal complex 11, Tuscany, Italy. PLoS ONE, 2019, 14, e0217500.	2.5	3
65	Carriage meningococcal isolates with capsule null locus dominate among high school students in a non-endemic period, Italy, 2012–2013. International Journal of Medical Microbiology, 2019, 309, 182-188.	3.6	7
66	Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data. BMC Infectious Diseases, 2019, 19, 281.	2.9	14
67	Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11) in Tuscany, Italy: a cross-sectional study. BMC Infectious Diseases, 2019, 19, 29.	2.9	15
68	Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015. Eurosurveillance, 2019, 24, .	7.0	59
69	Reconstruction of Dispersal Patterns of Hypervirulent Meningococcal Strains of Serogroup C:cc11 by Phylogenomic Time Trees. Journal of Clinical Microbiology, 2019, 58, .	3.9	8
70	Hospital discharges-based search of acute flaccid paralysis cases 2007–2016 in Italy and comparison with the National Surveillance System for monitoring the risk of polio reintroduction. BMC Public Health, 2019, 19, 1532.	2.9	17
71	The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area. BMC Infectious Diseases, 2019, 19, 1040.	2.9	27
72	An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B:cc11. Clinical Microbiology and Infection, 2019, 25, 111.e1-111.e4.	6.0	22

#	Article	IF	CITATIONS
73	Vaccine preventable invasive bacterial diseases in Italy: A comparison between the national surveillance system and recorded hospitalizations, 2007–2016. Vaccine, 2019, 37, 41-48.	3.8	21
74	Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Eurosurveillance, 2019, 24, .	7.0	59
75	Cocirculation of Hajj and non-Hajj strains among serogroup W meningococci in Italy, 2000 to 2016. Eurosurveillance, 2019, 24, .	7.0	11
76	Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015. Journal of Clinical Microbiology, 2018, 56, .	3.9	26
77	The impact of immunization programs on 10 vaccine preventable diseases in Italy: 1900–2015. Vaccine, 2018, 36, 1435-1443.	3.8	67
78	Molecular Characterization of Penicillinase–Producing Neisseria gonorrhoeae Isolated in Two Time Periods, 2003–2004 and 2014–2015, in Italy. Microbial Drug Resistance, 2018, 24, 621-626.	2.0	7
79	Diagnostic performance of commercial serological assays measuring Bordetella pertussis IgG antibodies. Diagnostic Microbiology and Infectious Disease, 2018, 90, 157-162.	1.8	5
80	Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infectious Diseases, 2018, 18, 609.	2.9	69
81	In the Digital Era, Is Community Outrage a Feasible Proxy Indicator of Emotional Epidemiology? The Case of Meningococcal Disease in Sardinia, Italy. International Journal of Environmental Research and Public Health, 2018, 15, 1512.	2.6	25
82	Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infectious Diseases, The, 2018, 18, 758-768.	9.1	164
83	Neisseria meningitidis Antimicrobial Resistance in Italy, 2006 to 2016. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
84	Reply to letters to the Editor. Vaccine, 2018, 36, 5508-5509.	3.8	0
85	Poliovirus and Other Enteroviruses from Environmental Surveillance in Italy, 2009–2015. Food and Environmental Virology, 2018, 10, 333-342.	3.4	38
86	Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy. Vaccine, 2018, 36, 4222-4227.	3.8	22
87	Interconnected clusters of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11), involving bisexuals and men who have sex with men, with discos and gay-venues hotspots of transmission, Tuscany, Italy, 2015 to 2016. Eurosurveillance, 2018, 23, .	7.0	21
88	Methodological approach towards a Gap Assessment of the Serbian microbiology system in the function of surveillance in line with EU standards and acquis. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 324-331.	0.4	0
89	Severe pertussis infection in infants less than 6 months of age: Clinical manifestations and molecular characterization. Human Vaccines and Immunotherapeutics, 2017, 13, 1073-1077.	3.3	21
90	Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence. Pathogens and Global Health, 2017, 111, 59-68.	2.3	148

#	Article	IF	CITATIONS
91	Acute flaccid paralysis surveillance in bosnia and herzegovina: Recent isolation of two sabin like type 2 poliovirus. Journal of Medical Virology, 2017, 89, 1678-1681.	5.0	2
92	The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine, 2017, 35, 2034-2041.	3.8	156
93	Clinical presentation and outcome of twenty cases of Invasive Meningococcal Disease due to Serogroup C – Clonal complex 11 in the Florence province, Italy, 2015–2016. Journal of Infection, 2017, 74, 210-213.	3.3	2
94	Genetic Resistance Determinants for Cefixime and Molecular Analysis of Gonococci Isolated in Italy. Microbial Drug Resistance, 2017, 23, 247-252.	2.0	6
95	Parents as source of pertussis transmission in hospitalized young infants. Infection, 2017, 45, 171-178.	4.7	29
96	Infants hospitalized for Bordetella pertussis infection commonly have respiratory viral coinfections. BMC Infectious Diseases, 2017, 17, 492.	2.9	23
97	Protection against Pertussis in Humans Correlates to Elevated Serum Antibodies and Memory B Cells. Frontiers in Immunology, 2017, 8, 1158.	4.8	24
98	Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015. BMC Infectious Diseases, 2017, 17, 617.	2.9	90
99	Does Breastfeeding Protect Young Infants From Pertussis? Case-control Study and Immunologic Evaluation. Pediatric Infectious Disease Journal, 2017, 36, e48-e53.	2.0	22
100	Meningococci of Serogroup X Clonal Complex 181 in Refugee Camps, Italy. Emerging Infectious Diseases, 2017, 23, 870-872.	4.3	16
101	Time trend analysis (2009-2016) of antimicrobial susceptibility in Neisseria gonorrhoeae isolated in Italy following the introduction of the combined antimicrobial therapy. PLoS ONE, 2017, 12, e0189484.	2.5	9
102	Pertussis in infants and the resurgence of a vaccine preventable disease: what to do? Commentary. Annali Dell'Istituto Superiore Di Sanita, 2017, 53, 100-103.	0.4	7
103	Molecular characterization of Neisseria gonorrhoeae on non-cultured specimens from multiple anatomic sites. Annali Dell'Istituto Superiore Di Sanita, 2017, 53, 213-217.	0.4	2
104	Pericarditis Caused by Hyperinvasive Strain ofNeisseria meningitidis, Sardinia, Italy, 2015. Emerging Infectious Diseases, 2016, 22, 1136-1137.	4.3	4
105	Genome-based study of a spatio-temporal cluster of invasive meningococcal disease due to Neisseria meningitidis serogroup C, clonal complex 11. Journal of Infection, 2016, 73, 136-144.	3.3	24
106	WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2) Tj ETQq0 0 0 rgBT /Ov Chemotherapy, 2016, 71, 3109-3116.	verlock 10 3.0	Tf 50 147 Td 81
107	Typing and surface charges of the variable loop regions of PorB from <i>Neisseria meningitidis</i> . IUBMB Life, 2016, 68, 488-495.	3.4	5
108	Impact of vaccination on meningococcal epidemiology. Human Vaccines and Immunotherapeutics, 2016,	3.3	22

12, 1051-1055.

7

#	Article	IF	CITATIONS
109	Low vaccine coverage among children born to HIV infected women in Niamey, Niger. Human Vaccines and Immunotherapeutics, 2016, 12, 540-544.	3.3	13
110	Molecular characterization of a collection of Neisseria meningitidis isolates from Croatia, June 2009 to January 2014. Journal of Medical Microbiology, 2016, 65, 1013-1019.	1.8	10
111	Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016. Eurosurveillance, 2016, 21, .	7.0	44
112	Poliomyelitis: residual hurdles to global eradication. Commentary. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 469-471.	0.4	5
113	Draft Genome Sequence of a Bordetella pertussis Strain with the Virulence-Associated Allelic Variant ptxP3 , Isolated in Italy. Genome Announcements, 2015, 3, .	0.8	3
114	Chlamydia trachomatis genotypes in school adolescents, Italy. Infection, 2015, 43, 739-741.	4.7	1
115	Imported and Indigenous cases of Invasive Meningocococcal Disease W:P1.5,2:F1-1: ST-11 in migrants' reception centers. Italy, June-November 2014. Advances in Experimental Medicine and Biology, 2015, 897, 81-83.	1.6	13
116	Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006–2014. Vaccine, 2015, 33, 3678-3681.	3.8	15
117	Pertussis in infants less than 6Âmonths of age and household contacts, Italy, April 2014. Human Vaccines and Immunotherapeutics, 2015, 11, 1173-1174.	3.3	5
118	Climate, demographic factors and geographical variations in the incidence of invasive meningococcal disease in Italy. Epidemiology and Infection, 2015, 143, 1742-1750.	2.1	8
119	Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013. Human Vaccines and Immunotherapeutics, 2015, 11, 2281-2286.	3.3	54
120	Vaccine coverage and determinants of incomplete vaccination in children aged 12–23 months in Dschang, West Region, Cameroon: a cross-sectional survey during a polio outbreak. BMC Public Health, 2015, 15, 630.	2.9	78
121	Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) Tj ETQq1	1	4 rgBT /Ovei
122	Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. BMC Infectious Diseases, 2015, 15, 321.	2.9	44
123	Draft Genome Sequence of Neisseria gonorrhoeae Sequence Type 1407, a Multidrug-Resistant Clinical Isolate. Genome Announcements, 2015, 3, .	0.8	4
124	Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13. PLoS ONE, 2015, 10, e0139376.	2.5	15
125	Persistent occurrence of serogroup Y/sequence type (ST)-23 complex invasive meningococcal disease among patients aged five to 14 years, Italy, 2007 to 2013. Eurosurveillance, 2015, 20, .	7.0	10
126	Twenty years of surveillance of Invasive Meningococcal Diseases in Puglia, Italy. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 366-70.	0.4	3

#	Article	IF	CITATIONS
127	Draft Genome Sequence of C:P1.5-1,10-8:F3-6:ST-11 Meningococcal Clinical Isolate Associated with a Cluster on a Cruise Ship. Genome Announcements, 2014, 2, .	0.8	0
128	Implications of Differential Age Distribution of Disease-Associated Meningococcal Lineages for Vaccine Development. Vaccine Journal, 2014, 21, 847-853.	3.1	19
129	Global Population Structure and Evolution of Bordetella pertussis and Their Relationship with Vaccination. MBio, 2014, 5, e01074.	4.1	257
130	Risk Factors for Antimicrobial-Resistant Neisseria gonorrhoeae in Europe. Sexually Transmitted Diseases, 2014, 41, 723-729.	1.7	33
131	Screening for Chlamydia trachomatis and Neisseria gonorrhoeae among high-school participants using the Versant CT/GC DNA 1.0 assay (kinetic PCR). Journal of Medical Microbiology, 2014, 63, 1237-1239.	1.8	1
132	Changing Antimicrobial Resistance Profiles among Neisseria gonorrhoeae Isolates in Italy, 2003 to 2012. Antimicrobial Agents and Chemotherapy, 2014, 58, 5871-5876.	3.2	16
133	Contrasting the anti-vaccine prejudice: a public health perspective. Commentary. Annali Dell'Istituto Superiore Di Sanita, 2014, 50, 6-9.	0.4	7
134	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases, The, 2013, 13, 416-425.	9.1	261
135	Bordetella pertussis in infants hospitalized for acute respiratory symptoms remains a concern. BMC Infectious Diseases, 2013, 13, 526.	2.9	24
136	Target Gene Sequencing To Define the Susceptibility of Neisseria meningitidis to Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2013, 57, 1961-1964.	3.2	37
137	Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines. Vaccine Journal, 2012, 19, 1609-1617.	3.1	59
138	Neisseria gonorrhoeae triggers the PGE2/IL-23 pathway and promotes IL-17 production by human memory T cells. Prostaglandins and Other Lipid Mediators, 2012, 99, 24-29.	1.9	5
139	The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines. Vaccine, 2012, 30, B73-B77.	3.8	14
140	Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010. Clinical Microbiology and Infection, 2012, 18, 558-564.	6.0	15
141	Update on antimicrobial susceptibility and genotype of Neisseria gonorrhoeae isolated in Italy. Diagnostic Microbiology and Infectious Disease, 2012, 72, 288-290.	1.8	4
142	Molecular characterization of Neisseria meningitidis B:NT:P1.14/162 clonal complex responsible of invasive meningococcal disease in the north of Italy. Diagnostic Microbiology and Infectious Disease, 2012, 72, 370-372.	1.8	1
143	High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. Eurosurveillance, 2012, 17, .	7.0	31
144	Emerging resistance inNeisseria meningitidisandNeisseria gonorrhoeae - Retracted. Expert Review of Anti-Infective Therapy, 2011, 9, 237-244.	4.4	9

#	Article	lF	CITATIONS
145	Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection. FEMS Immunology and Medical Microbiology, 2011, 61, 129-132.	2.7	26
146	Neisseria meningitidis rifampicin resistant strains: analysis of protein differentially expressed. BMC Microbiology, 2010, 10, 246.	3.3	13
147	Multicenter Study for Defining the Breakpoint for Rifampin Resistance in <i>Neisseria meningitidis</i> by <i>rpoB</i> Sequencing. Antimicrobial Agents and Chemotherapy, 2010, 54, 3651-3658.	3.2	37
148	Neisseria meningitidisSerogroup X Sequence Type 2888, Italy. Emerging Infectious Diseases, 2010, 16, 359-360.	4.3	10
149	Trend of ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Italy and analysis of the molecular determinants. Diagnostic Microbiology and Infectious Disease, 2010, 67, 350-354.	1.8	10
150	European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sexually Transmitted Infections, 2010, 86, 427-432.	1.9	53
151	Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. Journal of Antimicrobial Chemotherapy, 2009, 63, 1200-1204.	3.0	77
152	Serogroup C meningococci in Italy in the era of conjugate menC vaccination. BMC Infectious Diseases, 2009, 9, 135.	2.9	15
153	A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiologica, 2009, 32, 159-66.	0.1	23
154	Molecular characterization of nitrite reductase gene ( <i>ani</i> A) and gene product in <i>Neisseria meningitidis</i> isolates: ls <i>ani</i> A essential for meningococcal survival?. IUBMB Life, 2008, 60, 629-636.	3.4	25
155	Molecular analysis of tetracycline-resistant gonococci: rapid detection of resistant genotypes using a real-time PCR assay. FEMS Microbiology Letters, 2008, 286, 16-23.	1.8	9
156	Phenotypic and genotypic characterization of Neisseria gonorrhoeae in parts of Italy: detection of a multiresistant cluster circulating in a heterosexual network. Clinical Microbiology and Infection, 2008, 14, 949-954.	6.0	18
157	Sequencing penA Gene of Strains with Decreased Susceptibility to Penicillin (PenI) Improves Typing of Meningococcal Isolates. International Journal of Infectious Diseases, 2008, 12, e239-e240.	3.3	0
158	Characterization of invasive serogroup Y meningococci in Italy: prevalence of ST-23 Complex/Cluster A3. New Microbiologica, 2008, 31, 467-72.	0.1	6
159	Target Gene Sequencing To Characterize the Penicillin G Susceptibility of Neisseria meningitidis. Antimicrobial Agents and Chemotherapy, 2007, 51, 2784-2792.	3.2	103
160	Detection of resistance to rifampicin and decreased susceptibility to penicillin in Neisseria meningitidis by real-time multiplex polymerase chain reaction assay. Diagnostic Microbiology and Infectious Disease, 2007, 58, 241-244.	1.8	4
161	P807 Characterisation of the soluble domain of nitrite reductase from Neisseria meningitidis strains. International Journal of Antimicrobial Agents, 2007, 29, S203-S204.	2.5	0
162	Characterisation of invasive meningococcal isolates from Italian children and adolescents. Clinical Microbiology and Infection, 2007, 13, 100-103.	6.0	6

#	Article	IF	CITATIONS
163	Disseminated Gonococcal Infection in an Immunocompetent Patient Caused by an Imported Neisseria gonorrhoeae Multidrug-Resistant Strain. Journal of Clinical Microbiology, 2006, 44, 3833-3834.	3.9	8
164	Interlaboratory Comparison of PCR-Based Methods for Detection of Penicillin G Susceptibility in Neisseria meningitidis. Antimicrobial Agents and Chemotherapy, 2006, 50, 887-892.	3.2	11
165	Significant Gene Order and Expression Differences in Bordetella pertussis Despite Limited Gene Content Variation. Journal of Bacteriology, 2006, 188, 2375-2382.	2.2	67
166	Differential In Vitro Expression of the brkA Gene in Bordetella pertussis and Bordetella parapertussis Clinical Isolates. Journal of Clinical Microbiology, 2006, 44, 3397-3400.	3.9	21
167	Bordetella pertussis Inhibition of Interleukin-12 (IL-12) p70 in Human Monocyte-Derived Dendritic Cells Blocks IL-12 p35 through Adenylate Cyclase Toxin-Dependent Cyclic AMP Induction. Infection and Immunity, 2006, 74, 2831-2838.	2.2	56
168	Bordetella pertussis-Infected Human Monocyte-Derived Dendritic Cells Undergo Maturation and Induce Th1 Polarization and Interleukin-23 Expression. Infection and Immunity, 2005, 73, 1590-1597.	2.2	56
169	Inventory of the Proteins inNeisseriameningitidisSerogroup B Strain MC58. Journal of Proteome Research, 2005, 4, 1361-1370.	3.7	25
170	Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine, 2005, 23, 2494-2500.	3.8	40
171	Emergence in Italy of a Neisseria meningitidis Clone with Decreased Susceptibility to Penicillin. Antimicrobial Agents and Chemotherapy, 2004, 48, 3103-3106.	3.2	14
172	Long-Term Predominance of a Rare Meningococcal Phenotype in a Small Geographical Area. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 566-568.	2.9	0
173	Prediction of Decreased Susceptibility to Penicillin of Neisseria meningitidis Strains by Real-Time PCR. Journal of Clinical Microbiology, 2003, 41, 4666-4670.	3.9	22
174	Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough. Vaccine, 2003, 21, 1924-1931.	3.8	30
175	First Report of Capsule Replacement among Electrophoretic Type 37 Neisseria meningitidis Strains in Italy. Journal of Clinical Microbiology, 2003, 41, 5783-5786.	3.9	35
176	Serotype Distribution, Antibiotic Susceptibility, and Genetic Relatedness ofNeisseria meningitidisStrains Recently Isolated in Italy. Clinical Infectious Diseases, 2003, 36, 422-428.	5.8	23
177	Interlaboratory Comparison of Agar Dilution and Etest Methods for Determining the MICs of Antibiotics Used in Management of Neisseria meningitidis Infections. Antimicrobial Agents and Chemotherapy, 2003, 47, 3430-3434.	3.2	56
178	T-Cell Immune Response Assessment as a Complement to Serology and Intranasal Protection Assays in Determining the Protective Immunity Induced by Acellular Pertussis Vaccines in Mice. Vaccine Journal, 2003, 10, 637-642.	3.1	6
179	Role of immune sera in the in-vitro phagocytosis of Bordetella pertussis strains. Microbial Pathogenesis, 2002, 32, 135-141.	2.9	5
180	Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children Primed in Infancy With Acellular Vaccines. Pediatrics, 2001, 107, e25-e25.	2.1	37

#	Article	IF	CITATIONS
181	Sustained Efficacy During the First 6 Years of Life of 3-Component Acellular Pertussis Vaccines Administered in Infancy: The Italian Experience. Pediatrics, 2001, 108, e81-e81.	2.1	130
182	Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains. Journal of Antimicrobial Chemotherapy, 2001, 47, 219-222.	3.0	42
183	Cellâ€Mediated Immunity and Antibody Responses toBordetella pertussisAntigens in Children with a History of Pertussis Infection and in Recipients of an Acellular Pertussis Vaccine. Journal of Infectious Diseases, 2000, 181, 1989-1995.	4.0	72
184	Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology (United Kingdom), 1999, 145, 2069-2075.	1.8	126
185	Monitoring the genotype of meningococcal strains during an endemic period. Clinical Microbiology and Infection, 1999, 5, 748-752.	6.0	2
186	Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21–40 months of age. Vaccine, 1999, 17, 2030-2035.	3.8	5
187	Cell-Mediated Immune Responses in Four-Year-Old Children after Primary Immunization with Acellular Pertussis Vaccines. Infection and Immunity, 1999, 67, 4064-4071.	2.2	92
188	Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine, 1998, 16, 1270-1275.	3.8	60
189	<i>Bordetella parapertussis</i> Infection in Children: Epidemiology, Clinical Symptoms, and Molecular Characteristics of Isolates. Journal of Clinical Microbiology, 1998, 36, 999-1002.	3.9	72
190	Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughs. Journal of Clinical Microbiology, 1997, 35, 1550-1555.	3.9	51
191	Polymerase chain reaction for the identification of Bordetella pertussis and Bordetella parapertussis. Diagnostic Microbiology and Infectious Disease, 1996, 24, 197-200.	1.8	16
192	A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis. New England Journal of Medicine, 1996, 334, 341-349.	27.0	675
193	Polymerase chain reaction for the detection of Bordetella pertussis in clinical nasopharyngeal aspirates. Journal of Medical Microbiology, 1996, 44, 261-266.	1.8	24
194	Purification and characterization of an immunodominant 36 kDa antigen present on the cell surface of Clostridium difficile. Microbial Pathogenesis, 1992, 13, 271-279.	2.9	24